ACOG issues its most comprehensive menopause guidance yet: what the new recommendations actually say

On October 15, 2026, the American College of Obstetricians and Gynecologists (ACOG) published Clinical Practice Guideline 13, "Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms." ACOG describes it as the most comprehensive menopause guidance the organization has issued to date. It does not change what Kindr prescribes. It does reinforce, from one of the most influential bodies in women's health, the same guideline-concordant approach Kindr already follows: individualized hormone therapy when appropriate, real nonhormonal alternatives when it is not, and no role for unregulated supplements.

Why this guidance exists

ACOG cites figures that explain the scale of the problem it is addressing: 50–92% of women in menopause report vasomotor symptoms such as hot flashes and night sweats, 16–66% report menopause-related sleep disruption, and more than one-third of perimenopausal and postmenopausal women worldwide report depressive symptoms. ACOG President Camille A. Clare, MD, MPH, CPE, FACOG, said these symptoms can interfere with health, caregiving and careers, and called evidence-based access to care critical "as menopause misinformation continues to flourish."

Clearer timing guidance for hormone therapy

The updated guidance gives more detail on when to start hormone therapy to maximize benefit and limit risk. ACOG recommends that the decision be based on shared decision-making between patient and clinician, weighing symptoms, age, medical history, baseline cardiovascular disease, breast cancer and blood-clot risk, and the individual's own goals. If hormone therapy is selected, ACOG recommends starting it before age 60 or within 10 years of the start of spontaneous menopause, in people without contraindications.

That window mirrors the timing hypothesis already reflected in The Menopause Society's guidance and in how Kindr clinicians evaluate candidacy. It is not a mandate to start therapy, and it does not override an individual contraindication such as a personal history of certain cancers, unexplained bleeding, active liver disease, or a prior blood clot or stroke. Guideline coauthor Bruce Pier, MD, FACOG, noted that misconceptions about hormone-therapy risk have made some clinicians reluctant to prescribe it and some patients reluctant to consider it — which is part of why ACOG says the new guidance includes a fuller review of the evidence to support individualized counseling.

ACOG also addresses the other end of treatment: decisions about when and how to stop hormone therapy should be individualized, based on an ongoing reassessment of risk factors and a conversation between patient and clinician, not a fixed stopping age.

Nonhormonal options get a more detailed review

For people who have a contraindication to hormone therapy or prefer not to use it, ACOG's new guidance reviews evidence-based nonhormonal pharmacologic options. It highlights neurokinin receptor antagonists — fezolinetant and elinzanetant — as a newer therapeutic class for vasomotor symptoms, alongside SSRIs and SNRIs, which can help with both hot flashes and depressive symptoms in people experiencing one or both. Guideline coauthor Robert P. Kauffman, MD, MSCP, FACOG, said the goal was to cover hormonal, nonhormonal and nonpharmacologic options together so clinicians have what they need to help each patient individually.

ACOG also lists nonpharmacologic interventions with supporting evidence for vasomotor, sleep or mood symptoms: cognitive behavioral therapy, mindfulness-based interventions, exercise, clinical hypnosis and acupuncture. These are generally positioned as options that can be combined with hormonal or nonhormonal medication, not replacements for a clinical evaluation.

A direct statement on supplements

The guidance is unambiguous on one point relevant to the "meno-influencer" and wellness-supplement market: evidence does not support the safety or efficacy of phytoestrogens or herbal supplements for treating vasomotor or other menopausal symptoms. ACOG notes these products are heavily marketed and easy to access, but are not FDA-regulated and have not been tested for safety, efficacy or purity. Kindr does not sell or recommend proprietary blends for this reason.

Equity and access

ACOG's guidance also addresses health inequities in menopause care. Guideline author Catherine D. Cansino, MD, MPH, FACOG, said racial, cultural and socioeconomic factors affect both how people experience menopause and what care they receive, and that clinicians need to understand those barriers to close the gaps. ACOG also calls for earlier, more comprehensive patient education so people recognize symptoms and seek treatment sooner.

What this does not change

• It is not a new drug approval. Fezolinetant and elinzanetant are existing FDA-approved medications; ACOG is now giving them more detailed guidance coverage.
• It does not mean hormone therapy is right for everyone, or that every visit should end in a prescription.
• It does not cover genitourinary syndrome of menopause — ACOG says that guidance is still in development and expected in 2027.
• It is not a reason to start or stop any medication without a clinician visit.

The takeaway

ACOG's expanded guidance gives clinicians — and patients evaluating their own care — a clearer, more detailed reference for exactly the questions that matter most: when hormone therapy helps, when it does not fit, and what the real evidence-based alternatives are. It is consistent with the guideline-concordant approach described on our HRT guide and our clinical standards, including individualized screening before any prescription and no supplement blends.

Clinical review of this summary is pending. This article is educational and does not replace an individualized evaluation. Do not start, stop or change any medication based on this article.

Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team, led by Kevin Wolfe, CMO
NPI 1609792902 · Last reviewed: October 16, 2026